Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Schmittgall

- PMLiVE

Revlimid performance leads Celgene to trio of PMEAs

Wins Small Company of the Year thanks to work on rare cancer drug

Interview: Allan Hillgrove, Boehringer

Boehringer’s head of sales and marketing on access, partnerships and China on an important year for the German pharma company

- PMLiVE

Eisai lines-up Fycompa access programme for Germany

But sales suspension for epilepsy drug will continue

- PMLiVE

The evolution of IQWiG in Germany’s drug pricing policy

Over the past ten years Germany has created a well-oiled machine designed to ensure that it gets the best deal when it comes to drug prices

- PMLiVE

Langland and McCann big winners at 2013 IPA Best of Health Awards

Langland and McCann Health China both receive ‘Best of Show’ honours at awards to recognise creativity in healthcare adveritsing

- PMLiVE

Eisai pulls epilepsy drug Fycompa in Germany

Based on unfavourable assessment by pricing body

- PMLiVE

PMEA 2013 opens for entry

Programme recognises responsible marketing and business practice in the healthcare industry

- PMLiVE

Boehringer: Tough HTA threatens future of German research

Drug pricing system is stifling innovation says pharma company

- PMLiVE

GW Pharma says German Sativex pricing “unacceptable”

May pull MS drug from market

- PMLiVE

Bayer’s Eylea data not suitable, says IQWiG

German HTA body unhappy with Lucentis comparison data and turns down Bayer-Regeneron wet AMD drug

EISAI

Eisai “appalled” at decision not to recommend Fycompa in Germany

Regulator says pharma company filed inadequate comparison data for its epilepsy drug

- PMLiVE

Roche invests €200m in Munich biotech centre

Creates new jobs with expansion of German diagnostic production

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links